Testing NEO212 for brain tumors and metastases
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- If you take steroids for brain swelling, your dose has been stable or decreasing for at least 5 days before starting.
- You have a type of brain tumor (like astrocytoma or glioblastoma) or cancer that has spread to the brain and is not controlled by surgery or radiation.
- You are able to have an MRI or CT scan of your brain to check the tumor.
- You have adequate kidney, liver, and blood cell function.
- If you are a woman who can become pregnant, you agree to use birth control and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.
This trial tests a new drug called NEO100 for children with certain types of brain tumors. It is given through a needle into the tumor or nearby fluid, and the study looks at safety and the right dose.
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
This trial tests an oral drug called NBM-BMX for people with advanced solid tumors that have not responded to other treatments, or for people with newly diagnosed glioblastoma (a type of brain cancer). The study aims to see if the drug is safe and effective.
This early-phase study tests an oral medicine called ONC206 in adults with recurrent, rare brain or spinal cord tumors. The goal is to find a safe dose and look for signs the treatment can shrink or control the cancer.
Hear when a new Glioblastoma, IDH-wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.